Loading…
Employees: 30
Size Elixiron Immunotherapeutics (Cayman) (7871.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $477M, the 462nd largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$117.50 on 6 Nov 2026.
Performance Over six months the shares gained 61.6%, against -20.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 10,946.9% over the last twelve months (peer median -7.3%); the operating margin is -194.2% (peer median 4.0%).
Valuation It trades at 132.2× enterprise value to sales against a peer median of 3.1× (most expensive of 20).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | NT$113M | NT$50.3M | NT$803,000 | NT$25.7M |
| Revenue growth | — | +6,162% | -97% | — |
| Gross profit | NT$104M | NT$40.8M | -NT$7.18M | NT$19.7M |
| EBITDA | -NT$211M | -NT$187M | -NT$209M | -NT$117M |
| Net income | -NT$156M | -NT$1.11B | -NT$440M | NT$268M |
| Free cash flow | -NT$156M | -NT$132M | -NT$250M | -NT$106M |
| Capital expenditure | -NT$57,000 | NT$5.50M | NT$9.97M | NT$217,000 |
| Total debt | n/a | NT$24.9M | NT$1.38B | NT$778M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7871.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.1% | -11.3% | 4th lowest of 20 |
| 6-month return | +61.6% | -20.8% | 2nd highest of 19 |
| Distance from 52-week high | -36.5% | -41.5% | 6th highest of 20 |
| Revenue growth (TTM) | +10,946.9% | -7.3% | highest of 20 |
| Operating margin | -194.2% | 4.0% | 2nd lowest of 20 |
| EV / Sales | 132.2× | 3.1× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |